Kriya Presents Data at the 2025 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

UF startup Kriya Therapeutics, Inc., a biopharmaceutical company developing gene therapies to address chronic diseases affecting millions of people around the world, presented preclinical data on its gene therapy candidate, KRIYA-825, being developed for the treatment of Geographic Atrophy. The data were presented at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Salt Lake City, UT.

KRIYA-825 is an adeno-associated virus (AAV)-based gene therapy that expresses a complement CR2-CR1 fusion protein for the treatment of Geographic Atrophy, a prevalent degenerative retinal disease that is one of the leading causes of blindness among the elderly. The CR2-CR1 fusion protein is designed to inhibit the activity of complement C3 and C5, which are validated therapeutic pathways that have been targeted by two different FDA approved medicines for Geographic Atrophy. Earlier this year, Kriya initiated a clinical trial of KRIYA-825 in patients with Geographic Atrophy.

Read more about Kriya Presents Data at the 2025 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting.